Skip to content

Immunodysregulation As an Expression of Underlying Inborn Errors of Immunity: Implementation of Diagnostics and Management of Pediatric and Adult Patients with Immune System Disorders

Immunodysregulation As an Expression of Underlying Inborn Errors of Immunity: Implementation of Diagnostics and Management of Pediatric and Adult Patients with Immune System Disorders

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06773546
Enrollment
400
Registered
2025-01-14
Start date
2023-09-15
Completion date
2026-12-31
Last updated
2025-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inborn Errors of Immunity

Keywords

Inborn errors of immunity

Brief summary

This is an observational, retro-prospective, moncentric study focused on Inborn Errors of Immunity, an heterogeneous group of inherited diseases due to defects in the differentiation and/or function of the immune system. The primary aim of this study is to obtain a clinical-immunological, functional and molecular characterisation of paediatric and adult patients with confirmed or suspected Inborn Errors of Immunity, particularly of patients with manifestations of immunedysregulation, focusing on clinical course, immunophenotypic laboratory and functional abnormalities, genetic background.

Detailed description

Due to the observational nature of the study, patients were and will be treated according to normal clinical practice and in accordance with medical judgement. The following evaluations were performed in the retrospective cohort and will be performed in the prospective cohort: * Standard haematochemical examinations; * Extended lymphocyte typing; * Plasma dosage of immunoglobulins; * Evaluation of early and late responses to Measles-Parotitis-Rosolia and Diphtheria-Tetanus-Pertussis vaccinations; * Evaluation of antibody responses to vaccines against Haemophilus Influenzae, Neisseria Meningitidis and Pneumococcus; * Detection of auto-antibodies on HEp-2 cells, and of auto-antibodies directed against haemopoietic cells and proteins of innate and adaptive immunity; * Plasma dosage of complement factors (C3, C4); * Radiological assessment; * Functional immunological assay; * Molecular-genetic investigations of targeted gene panels involved in immunodysregulation and Inborn Errors of Immunity.

Interventions

None listed

Sponsors

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
No minimum to 50 Years
Healthy volunteers
No

Inclusion criteria

* patients with confirmed or suspected Inborn Errors of Immunity; * age \< 50 years at onset of clinical features suspected for Inborn Errors of Immunity; * obtaining informed consent from patients or parents/legal guardian of pediatric patients.

Exclusion criteria

• patients in whom infectious susceptibility and immunodysregulation can only be attributed to known non-immunological causes: acquired immunodeficiency secondary to chronic infections (HIV), and acquired immunodeficiency secondary to immunosuppressive treatment.

Design outcomes

Primary

MeasureTime frameDescription
Category of diagnsoed Inborn Error of Immunityat baselinecategories I to X
Qualitative or quantitative alterations in innate immunity and/or adaptive immunityat baselinepresence or absence of alterations
Infective susceptibilityat baseline and every 6 months up to 1 yearpresence of one of the following conditions: invasive, severe, persistent, recurrent, opportunistic and/or vaccine strain infections
Immunodisregulationat baseline and every 6 months up to 1 yearpresence of at least one disorder among atopy, hyperinflammation, autoimmunity, non-clonal lymphoproliferation and/or malignant neoplasms
Mortality1 year after diagnosis of Inborn Errors of Immunitytime-to-event from diagnosis of Inborn Errors of Immunity up to 1 year

Countries

Italy

Contacts

Primary ContactFrancesca Conti
francesca.conti27@unibo.it00390512144666

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026